Dexcom G7 Continuous Glucose Monitoring System Recall
Areazine synthesizes this FDA recall directly from FDA's official public data feed. See our methodology for full source attribution and refresh cadence.
Dexcom, Inc. is recalling two lots of Dexcom G7 sensors that were stolen and sold after being designated for destruction.
What this FDA recall tells you, and what most readers miss
This notice was issued by FDA on August 4, 2026 and geographically references United States. Its severity classification of "medium" signals how the issuing agency weighs the risk of harm if no action is taken - "critical" and "high" tier alerts typically carry direct consumer actions, while "medium" and "low" tend toward informational guidance or monitoring advisories. The category it belongs to - FDA Recalls - determines the consumer-protection framework behind it, which shapes what remedies (refunds, replacements, repairs, or the recall itself) are available to affected consumers and which agency holds statutory responsibility for enforcement.
Most readers skim a notice like this, check whether they are personally affected, and move on. The more useful lens is to verify its scope, source, and timestamp, then compare related notices without assuming that one record proves a broader trend.
Areazine pairs this record with the original agency URL so you can check the primary source before acting. Its related labels are recall, product-safety, fda, Medical Devices.
What Happened
Certain lots of Dexcom G7 sensors originally designated as scrap and intended for destruction were stolen during the destruction process. The sensors were later sold to pharmacies and distributors by Pharmsource, LLC.
Which Products Are Affected
- Brand Name: Dexcom G7 Continuous Glucose Monitoring System
- Product Name: Dexcom G7 US Retail Sensor/Transmitter 1-pack
- Model/Catalog Number: STP-AT-012
- UDI-DI: 00386270004109
- Lot Numbers: 1725204004 and 1725069002
Lot 1725204004 has sensor session starts in the United States. Lot 1725069002 has sensor session starts in the United States and the countries of Australia, Austria, Canada, Czech Republic, Finland, France, Germany, Hong Kong, Israel, Italy, Japan, South Korea, Kuwait, Netherlands, Poland, Portugal, Qatar, Singapore, Spain, Switzerland, Turkey, United Arab Emirates, and the United Kingdom.
What You Should Do
Consumers should check their device lot numbers against the affected lots listed in the recall.
Why This Matters
Lot 1725204004 sensors were not properly sterilized and have an increased risk of skin infection if used. Lot 1725069002 sensors have an increased risk of having no sensor readings available or experiencing sensor inaccuracy that includes the potential for missed detection of a hyperglycemic event or incorrect treatment decisions.
Source
FDA Recall Z-2574-2026 - Dexcom, Inc., Class II recall initiated May 27, 2026.
Original source: FDA Official Notice ↗
Related FDA Recalls
All FDA Recalls →Nationwide notices with similar length or severity timing 8
Two Areazine-derived peer sets for this FDA recall: nearest notices by body length and by same severity near the same agency date. Peers come from other categories so they are not the same-feed Related list above.
Similar body length
Nearest notices by article body length (1,470 characters here).
Similar severity timing
Same severity (medium) notices issued closest in time to August 4, 2026.
Frequently Asked Questions
Common questions about this FDA recall.